Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

Patients with SSc who have gastric dysmotility present with a more severe disease phenotype and are associated with an increased risk for adverse outcomes.

SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) ...

A lower initial lung diffusion capacity for carbon monoxide is associated with a higher rate of progression from very early diagnosis to definite systemic sclerosis.

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

SAQE, an innovative tool achieving over 90% accuracy in diagnosing Hypersensitivity Pneumonitis, a serious lung condition ...